Anika Therapeutics, Inc. (ANIK)
19.10
-0.26
(-1.34%)
USD |
NASDAQ |
Oct 02, 16:00
19.12
+0.02
(+0.10%)
After-Hours: 20:00
Anika Therapeutics EPS Diluted (Quarterly) : 0.2412 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.2412 |
| March 31, 2026 | -0.3737 |
| December 31, 2025 | 0.0199 |
| September 30, 2025 | -0.1615 |
| June 30, 2025 | -0.2764 |
| March 31, 2025 | -0.3408 |
| December 31, 2024 | -1.50 |
| September 30, 2024 | -2.026 |
| June 30, 2024 | -0.0059 |
| March 31, 2024 | -0.3071 |
| December 31, 2023 | -4.30 |
| September 30, 2023 | -0.4493 |
| June 30, 2023 | -0.1866 |
| March 31, 2023 | -0.7063 |
| December 31, 2022 | -0.3352 |
| September 30, 2022 | -0.2859 |
| June 30, 2022 | -0.1953 |
| March 31, 2022 | -0.2028 |
| December 31, 2021 | -0.4012 |
| September 30, 2021 | 0.0381 |
| June 30, 2021 | 0.4465 |
| March 31, 2021 | 0.1966 |
| December 31, 2020 | -1.097 |
| September 30, 2020 | -0.4513 |
| June 30, 2020 | -0.5429 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.4036 |
| December 31, 2019 | 0.2771 |
| September 30, 2019 | 0.6395 |
| June 30, 2019 | 0.6697 |
| March 31, 2019 | 0.3149 |
| December 31, 2018 | 0.5397 |
| September 30, 2018 | 0.53 |
| June 30, 2018 | 0.68 |
| March 31, 2018 | -0.46 |
| December 31, 2017 | 0.53 |
| September 30, 2017 | 0.46 |
| June 30, 2017 | 0.76 |
| March 31, 2017 | 0.37 |
| December 31, 2016 | 0.54 |
| September 30, 2016 | 0.59 |
| June 30, 2016 | 0.57 |
| March 31, 2016 | 0.45 |
| December 31, 2015 | 0.72 |
| September 30, 2015 | 0.55 |
| June 30, 2015 | 0.51 |
| March 31, 2015 | 0.23 |
| December 31, 2014 | 0.51 |
| September 30, 2014 | 0.40 |
| June 30, 2014 | 0.60 |
| March 31, 2014 | 0.97 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Precigen, Inc. | 0.0485 |
| Repligen Corp. | 0.0884 |
| Amgen, Inc. | 4.366 |
| Biogen, Inc. | 0.6557 |
| BioMarin Pharmaceutical, Inc. | 0.2302 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 3.309M |
| Revenue (Quarterly) | 32.61M |
| Total Expenses (Quarterly) | 29.30M |
| Enterprise Value | 242.45M |
| Gross Profit Margin (Quarterly) | 65.15% |
| Profit Margin (Quarterly) | 10.15% |
| Earnings Yield | -1.44% |
| Normalized Earnings Yield | -1.435 |